Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis
- 1 January 2009
- journal article
- research article
- Published by Taylor & Francis Ltd in Leukemia & Lymphoma
- Vol. 50 (5), 764-772
- https://doi.org/10.1080/10428190902856824
Abstract
The role of intravenous immunoglobulins (IVIG) prophylaxis in hypogammaglobulinemic patients with lymphoproliferative disorders (LPD) and plasma cell dyscrasias (PCD) has not been established. We performed a systematic review and meta-analysis of randomized-controlled trials comparing prophylaxis with polyvalent IVIG versus control. The primary outcomes were all-cause mortality and major infections. Nine trials, assessing patients with chronic lymphocytic leukemia (CLL) and multiple myeloma (MM), were included. No survival benefit could be demonstrated, RR 1.36 (95% CI 0.58–3.19, two trials), but there was a significant decrease in the occurrence of major infections, RR 0.45 (95% CI 0.27–0.75, three trials) and a significant reduction in clinically documented infections, RR 0.49 (95% CI 0.39–0.61, three trials). Adverse events, usually not requiring discontinuation of IVIG, occurred significantly more with IVIG. On the basis of the available data, IVIG cannot be recommended routinely for patients with CLL or MM with hypogammaglobulinemia and/or recurrent infections and should be considered on individual basis.This publication has 13 references indexed in Scilit:
- Randomized trial of intravenous immunoglobulin prophylaxis for patients with chronic lymphocytic leukaemia and secondary hypogammaglobulinaemiaClinical and Laboratory Haematology, 2008
- PROPHYLAXIS AGAINST INFECTIONS WITH INTRAVENOUS IMMUN0GLOBULINS IN MULTIPLE MYELOMABritish Journal of Haematology, 1995
- Immunoglobulin replacement in patients with chronic lymphocytic leukaemia: a comparison of two dose regimesBritish Journal of Haematology, 1994
- Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myelomaThe Lancet, 1994
- Cost Effectiveness of Prophylactic Intravenous Immune Globulin in Chronic Lymphocytic LeukemiaThe New England Journal of Medicine, 1991
- Hypogammaglobulinaemia in Low Grade B Cell Tumours; Significance and TherapyImmunological Investigations, 1991
- Consensus on IVIGThe Lancet, 1990
- Intravenous Immunoglobulin for the Prevention of Infection in Chronic Lymphocytic LeukemiaThe New England Journal of Medicine, 1988
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986
- Role of Gamma Globulin for Immunoprophylaxis in Multiple MyelomaThe New England Journal of Medicine, 1967